BLU-956

BLU-956 is a next-generation, small molecule cyclin-dependent kinase 2 (CDK2) inhibitor developed by Blueprint Medicines. It is being investigated as an antineoplastic agent, specifically targeting cell cycle regulation in cancer cells. The drug is designed to inhibit CDK2 activity, which plays a critical role in cell proliferation and tumor growth. As of mid-2025, BLU-956 remains in preclinical development with a primary focus on hormone receptor-positive (HR+), HER2-negative breast cancer and potentially other solid tumors where CDK2 vulnerability has been identified[1][3][4][8][9]. Blueprint Medicines aims for this candidate to address resistance mechanisms that emerge following treatment with existing CDK4/6 inhibitors.